CAPhO 2026 Clinical Conversations: Elevating Care in Double-Exposed CLL/SLL

Lilly Canada Sponsored Symposium

This interactive, case-based session examines the management of double-exposed CLL/SLL in patients who have progressed after BTK and BCL-2 inhibitor therapy. Through real-world scenarios, participants will explore current challenges, compare treatment strategies, and identify practical approaches to improving outcomes. The discussion will highlight clinically relevant differences in efficacy and toxicity, potential drug interactions, and evidence-based recommendations to support personalized care. Attendees will gain actionable insights to apply best practices and confidently navigate complex therapeutic decisions in a rapidly evolving treatment landscape.

Be part of the conversation as we explore the evolving treatment landscape and strategies to optimize patient outcomes in double-exposed CLL/SLL